Viridian Therapeutics, Inc.VRDNNASDAQ

Revenue (LTM)

$71M

+23359.9% YoY

Net Income (LTM)

$-343M

-26.9% YoY

Free Cash Flow

$-277M

Revenue CAGR (5Y)

+132.2%

—Marginsstable

FCF($0.3B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	3	2↓40.2%	0↓82.3%	0↓3.8%	71↑23359.9%
Gross Profit	3	2↓40.2%	0↓82.3%	0↓3.8%	70↑22975.8%
Operating Income	-80	-134↓68.5%	-254↓89.5%	-299↓17.5%	-363↓21.5%
Net Income	-79	-130↓63.5%	-238↓83.0%	-270↓13.6%	-343↓26.9%
EBITDA	-79	-129↓62.9%	-235↓82.3%	-266↓12.9%	-336↓26.7%
EPS Diluted	-6.66	-3.91↑41.3%	-5.31↓35.8%	-3.98↑25.0%	-3.32↑16.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	42	156↑267.8%	103↓33.9%	100↓3.1%	212↑113.2%
Total Current Assets	200	425↑112.1%	486↑14.6%	738↑51.8%	894↑21.1%
Total Assets	204	435↑113.6%	490↑12.7%	742↑51.4%	899↑21.1%
Total Current Liabilities	14	33↑144.6%	27↓20.1%	48↑79.7%	71↑47.7%
Total Liabilities	16	40↑150.3%	48↑20.9%	71↑46.2%	177↑150.5%
Total Equity	188	395↑110.5%	442↑11.9%	672↑51.9%	722↑7.5%
Total Debt	1	5↑911.2%	21↑300.3%	21↑0.2%	51↑140.3%
Net Debt	-42	-150↓259.8%	-82↑45.6%	-78↑4.0%	-162↓106.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-55	-94↓71.9%	-184↓96.3%	-232↓26.1%	-276↓19.0%
Capital Expenditure	-0	-1↓135.8%	-1↓12.7%	-1↑43.1%	-0↑3.1%
Free Cash Flow	-55	-95↓72.3%	-185↓95.6%	-233↓25.8%	-277↓18.9%
Stock-Based Comp	14	20↑36.6%	67↑239.9%	42↓37.3%	44↑5.1%
Net Change in Cash	-4	113↑3248.4%	-53↓146.6%	-3↑93.9%	113↑3588.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance